Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials

Heart failure (HF) therapy trials usually exclude cancer patients. We examined the association between cancer history and outcomes in trial participants with HF and reduced (HFrEF) or preserved ejection fraction (HFpEF).

• Publication year

  2023

• Venue

  European Journal of Heart Failure

• Publication date

  2023-03-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ejhf.2818PMID 36919816PMCID PMC10947056
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer Incidence and Mortality According to Pre-Existing Heart Failure in a Community-Based Cohort

  2022cited by this paper
• Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction

  2021cited by this paper
• Reverse Cardio‐Oncology: Cancer Development in Patients With Cardiovascular Disease

  2020cited by this paper
• Cancer Mortality in Trials of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta‐Analysis

  2020cited by this paper
• Prevalence and incidence of various cancer subtypes in patients with heart failure vs matched controls.

  2020cited by this paper
• Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.

  2020cited by this paper
• Prevalence and incidence of various Cancer subtypes in patients with heart failure vs matched controls.

  2020cited by this paper
• Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study.

  2019cited by this paper
• Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases

  2019cited by this paper
• A population-based study of cardiovascular disease mortality risk in US cancer patients.

  2019cited by this paper
• Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.

  2019cited by this paper
• Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)

  2018cited by this paper
• Linking Heart Failure to Cancer: Background Evidence and Research Perspectives

  2018cited by this paper
• Declining Risk of Sudden Death in Heart Failure

  2017cited by this paper
• Declining Risk of Sudden Death in Heart Failure.

  2017cited by this paper
• Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.

  2017cited by this paper
• 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).

  2016cited by this paper
• Incidence of cancer in patients with chronic heart failure: a long‐term follow‐up study

  2016cited by this paper
• Cardiovascular Toxic Effects of Targeted Cancer Therapies.

  2016cited by this paper
• Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure.

  2016cited by this paper
• 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: a population-based study.

  2015cited by this paper
• Angiotensin-neprilysin inhibition versus enalapril in heart failure.

  2014cited by this paper
• Patients with heart failure have an increased risk of incident cancer.

  2013cited by this paper
• Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction.

  2012cited by this paper
• Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals

  2011cited by this paper
• Eplerenone in patients with systolic heart failure and mild symptoms.

  2011cited by this paper
• Population Impact of Heart Failure and the Most Common Forms of Cancer: A Study of 1 162 309 Hospital Cases in Sweden (1988 to 2004)

  2010cited by this paper
• Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials.

  2010cited by this paper
• Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

  2003cited by this paper
• More ‘malignant’ than cancer? Five‐year survival following a first admission for heart failure

  2001cited by this paper
• Effect of carvedilol on survival in severe chronic heart failure.

  2001cited by this paper
• The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

  2000cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.

  1999cited by this paper
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

  1999cited by this paper
• Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

  1991cited by this paper

• Influence of a history of malignancy on the long-term survival of abdominal aortic aneurysm patients with indication for an elective repair.

  2025cites this paper
• What's new in heart failure? November 2025

  2025cites this paper
• Association of cardiorespiratory fitness with risk of adverse cardiovascular outcomes in cancer patients: a cohort study

  2025cites this paper
• How to utilize current guidelines to manage patients with cancer at high risk for heart failure

  2024cites this paper
• Cardio-Oncology and Heart Failure: A Scientific Statement from the Heart Failure Society of America.

  2024cites this paper
• Use of heart failure medical therapy before and after a cancer diagnosis: A longitudinal study

  2024cites this paper
• Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence

  2024cites this paper
• 2024 update in heart failure

  2024influential citation
• April 2023 at a glance: focus on diagnosis and comorbidities

  2023cites this paper
• Shared and Reciprocal Mechanisms Between Heart Failure and Cancer　- An Emerging Concept of Heart-Cancer Axis.

  2023cites this paper
• When and how? Two simple questions to determine cancer status and inform therapeutic decisions and trial design in heart failure

  2023cites this paper